Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

FTC settlement to spark aspirin ads from Bayer

Published on .

Bayer Corp. agreed to launch a $1 million consumer education campaign to settle Federal Trade Commission charges that the company made unsubstantiated claims about the appropriateness of using aspirin for prevention of heart attacks and strokes. Page ads in magazines to run from February through May will promote a phone number to obtain a brochure that says in part "aspirin is not appropriate for everyone." As part of the FTC settlement, Bayer also settled cases with New York and Connecticut attorneys general that included $30,000 payments to both states. In 1985, Bayer's U.S. predecessor agreed to an FTC order barring it from making therapeutic claims without competent and reliable evidence.

Copyright January 2000, Crain Communications Inc.

Most Popular
In this article: